Blockchain could galvanize COVID-19 impacted healthcare supply chains: GlobalData
Blockchain technology could prove to be the missing link for global healthcare supply chains exposed by the COVID-19 pandemic in building resilience and galvanizing efficiency, transparency and authenticity, according to market research firm, GlobalData.
The COVID-19 pandemic has wreaked havoc on almost every part of the healthcare industry's supply chains and has rendered many organizations -- especially those who rely heavily on markets such as India and China for raw materials or finished products -- vulnerable, the firm said.
The current outbreak has, therefore, created a "huge stress test" for the healthcare industry and the desperate need for change, said Urte Jakimaviciute, Senior Director of Market Research at GlobalData. "Lack of supply chain efficiency, transparency and authenticity has been an ongoing issue and the root of many challenges faced by the healthcare companies."
GlobalData cited numerous instances of faulty and counterfeit goods entering markets, which has exacerbated and weakened the global fight against COVID-19: faulty China-produced protective masks and testing kits have been reported by EU countries such as Spain and the Netherlands; Australian Border Force has reportedly seized consignments of personal protective equipment (PPE) that was counterfeit or defective; and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has disabled nine domain names and social media accounts that were selling fake or unauthorized COVID-19 products.
Unless all points in the supply chain are transparent, identifying the source of the transgression or verifying the authenticity of the product is difficult, GlobalData said.
According to Jakimaviciute, healthcare organizations, from manufacturers to distributors, could use blockchain-based systems, which would provide an "open, tamper-proof, distributed record of transactions" and, in turn, "increase accuracy and efficiency".
"Blockchain has broad implications for the healthcare industry. More cases have recently emerged due to the need to simplify and improve security and accuracy for cumbersome, inefficient supply chain processes. While it may be too late to incorporate any sizable blockchain-related solutions to manage the impact of the coronavirus on supply chains, as the technology is still in a proof-of-concept stage, blockchain remains as one of the most promising solutions to facilitate data sharing, improve regulatory compliance and adherence with serialization regulations,” Jakimaviciute concluded.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance